Investment Attraction Strategies for Bio Startups
Securing investment is one of the most critical challenges facing bio startups. The bio sector is characterized by long development timelines, high capital requirements, and significant regulatory risk, making investor education and relationship management especially important. This guide provides practical strategies for bio startups seeking to attract investment.
Bio Investment Landscape
Korea bio VC investment trends: Venture capital investment in Korea's bio sector has grown steadily, reaching approximately KRW 2.5 trillion in recent years, with particular focus on cell and gene therapy, AI-driven drug discovery, and medical devicesAverage deal size: Series A rounds for bio startups typically range from KRW 3 billion to KRW 10 billion, while Series B and beyond can reach KRW 20-50 billionInvestment cycle: Bio investments often follow a longer cycle than tech startups, with investors expecting a 7-10 year horizon to exitGlobal context: Korean bio startups increasingly attract international investors, particularly for companies with global regulatory strategiesInvestor Types
Understanding different investor types helps tailor your pitch and partnership approach:
Venture capital (VC): Dedicated bio/healthcare VCs bring deep domain expertise, industry networks, and patient capital suited to long development timelinesCorporate VC (CVC): Pharmaceutical and healthcare company venture arms invest strategically, often seeking pipeline candidates or technology platforms that complement their businessGovernment funds: Korea Investment Corporation, KVIC, and ministry-affiliated funds provide growth capital with favorable terms, often co-investing alongside private VCsAngel investors: High-net-worth individuals with bio/pharma backgrounds can provide early-stage capital and valuable mentorship, though typically in smaller amountsPitch Preparation
A compelling bio startup pitch must balance scientific rigor with business storytelling:
Scientific narrative: Clearly explain the unmet medical need, your scientific approach, and why it is differentiated. Avoid excessive jargon while demonstrating deep understandingClinical and regulatory milestones: Present a clear, realistic timeline of development milestones, including IND filing, clinical trial phases, and anticipated regulatory approvalsTeam credibility: Highlight the founding team's relevant credentials, industry experience, and advisory board members with recognized expertiseMarket opportunity: Quantify the addressable market with credible data sources, and explain your go-to-market strategy or partnering planFinancial projections: Provide realistic financial models showing capital needs, key value inflection points, and potential return scenariosDue Diligence Readiness
Being well-prepared for investor due diligence significantly accelerates the investment process:
IP audit: Ensure your patent portfolio is well-organized, with clear ownership, freedom-to-operate opinions, and a filing strategy covering key marketsRegulatory strategy: Document your regulatory pathway for each target market, including pre-IND meeting plans and anticipated regulatory requirementsFinancial projections: Prepare detailed financial models with clearly stated assumptions, sensitivity analyses, and multiple scenario projectionsLegal housekeeping: Ensure corporate governance, employment agreements, and licensing contracts are properly documented and up to dateData room preparation: Organize all key documents in a virtual data room for efficient due diligence reviewNegotiation Tips
Valuation methods: Pre-revenue bio companies are typically valued using risk-adjusted Net Present Value (rNPV) or comparable transaction analysis rather than revenue multiplesTerm sheet key clauses: Pay particular attention to liquidation preferences, anti-dilution provisions, board composition, and protective provisionsMilestone-based tranching: Consider structuring investment in tranches tied to development milestones, which can align interests and potentially improve overall termsInvestor value-add: Evaluate investors not just on valuation but on the strategic value they bring, including industry connections, regulatory expertise, and follow-on funding capabilityLegal counsel: Engage experienced biotech transaction attorneys to review terms and protect founder interests while maintaining investor confidenceHow KITIM Can Help
KITIM assists bio startups with investment readiness assessment, pitch deck development, investor introductions, and government funding applications. Our team has supported numerous bio companies in securing both private and public funding. Contact us to discuss your fundraising strategy.
